These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1422489)

  • 1. Urate metabolism during bone marrow transplantation.
    Cannell PK; Herrmann RP
    Bone Marrow Transplant; 1992 Oct; 10(4):337-9. PubMed ID: 1422489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.
    Hovi L; Saarinen-Pihkala UM; Vettenranta K; Lipsanen M; Tapanainen P
    Bone Marrow Transplant; 1999 Nov; 24(10):1131-6. PubMed ID: 10578163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
    Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
    Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation for acute lymphocytic leukemia utilizing total body irradiation followed by high doses of cytosine arabinoside: lack of superiority over cyclophosphamide-containing conditioning regimens.
    Woods WG; Ramsay NK; Weisdorf DJ; Haake R; Vallera DA; Kim TH; Lasky L; Nesbit ME; Bostrom B; Uckun F
    Bone Marrow Transplant; 1990 Jul; 6(1):9-16. PubMed ID: 2202462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of busulfan/cyclophosphamide preparative regimens.
    Santos GW
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):12-6; quiz 17. PubMed ID: 8342070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy.
    Meloni G; De Fabritiis P; Carella AM; Mangoni L; Porcellini A; Marmont A; Mandelli F
    Bone Marrow Transplant; 1990 Jan; 5(1):29-32. PubMed ID: 2404528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity?
    Emminger W; Emminger-Schmidmeier W; Peters C; Hawliczek R; Höcker P; Gadner H
    Bone Marrow Transplant; 1991 Aug; 8(2):119-23. PubMed ID: 1933052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
    Crilley P; Topolsky D; Styler MJ; Bernstein E; Resnick K; Mullaney R; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1995 Mar; 15(3):361-5. PubMed ID: 7599559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
    Devine SM; Geller RB; Holland HK; Wingard JR; Saral R
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):56-63; quiz 64. PubMed ID: 8342077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
    Carlson K; Smedmyr B; Hagberg H; Oberg G; Simonsson B
    Bone Marrow Transplant; 1993 Mar; 11(3):205-8. PubMed ID: 8467284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulphan and melphalan prior to autologous bone marrow transplantation.
    Srivastava A; Bradstock KF; Szer J; de Bortoli L; Gottlieb DJ
    Bone Marrow Transplant; 1993 Oct; 12(4):323-9. PubMed ID: 8275031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.